Recurrent Prostate Carcinoma Clinical Trial
Official title:
Correlation of Serum Catecholamine With Emotional Stress in Men With Prostate Cancer: A Pilot Study
This pilot research trial studies the collection of serum samples in studying emotional stress in patients with prostate cancer. Studying serum samples from patients with prostate cancer in the laboratory may help doctors determine if levels of epinephrine and cortisol, substances the body makes when stressed, rise or fall with how patients are feeling and/or if those levels are related to clinical information related to prostate cancer.
PRIMARY OBJECTIVES: I. To determine if serum epinephrine or cortisol levels in men with prostate cancer correlate with perceived stress or distress over time in two to five consecutive visits. SECONDARY OBJECTIVES: I. To determine the change in serum epinephrine levels in men with prostate cancer over time in two to five consecutive visits. II. To determine the change in serum cortisol levels in men with prostate cancer over time in two to five consecutive visits. III. To determine the change in levels of stress in men with prostate cancer over time in two to five consecutive visits IV. To determine the change in levels of distress in men with prostate cancer over time in two to five consecutive visits. TERTIARY OBJECTIVES: I. To determine if serum epinephrine or cortisol levels in men with prostate cancer correlate with prostate cancer progression two to five visits. OUTLINE: Patients undergo collection of serum samples for epinephrine and cortisol levels at baseline and 4 clinical visits. Patients also receive the Self-Perceived Stress questionnaire and the Distress Thermometer questionnaire to measure perceived stress. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04457232 -
Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation
|
Phase 1 | |
| Active, not recruiting |
NCT03796767 -
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
|
Phase 2 | |
| Withdrawn |
NCT05034562 -
Gallium-68 PSMA-11 PET in Participants With Prostate Cancer
|
Phase 2 | |
| Completed |
NCT00936975 -
Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases
|
Phase 2 | |
| Active, not recruiting |
NCT00486642 -
Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
|
Phase 2 | |
| Completed |
NCT02940262 -
Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy
|
Phase 3 | |
| Completed |
NCT01787331 -
Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02807805 -
Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
|
Phase 2 | |
| Completed |
NCT01026623 -
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT00536991 -
Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02522715 -
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04514484 -
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
|
Phase 1 | |
| Terminated |
NCT02985021 -
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
|
Phase 2 | |
| Active, not recruiting |
NCT02312557 -
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
|
Phase 2 | |
| Active, not recruiting |
NCT01953640 -
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
|
||
| Completed |
NCT02673151 -
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
|
Phase 2/Phase 3 | |
| Completed |
NCT00064129 -
Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer
|
Phase 1 | |
| Recruiting |
NCT04519879 -
White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA
|
Phase 2 | |
| Recruiting |
NCT03016741 -
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
|
Phase 4 | |
| Completed |
NCT01576172 -
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
|
Phase 2 |